BERKELEY HEIGHTS, N.J., Feb. 12 /PRNewswire/ -- Clinsys, Inc., today announced that it is changing its name to Clinsys Clinical Research, Inc. to reflect its more focused corporate direction, clearly defined global strategy and clinical operations capabilities.
“In order to effectively meet the expectations of our sponsors we have integrated our global operations under one platform giving us increased capabilities with greater efficiency and enhanced quality,” said David E. Williams, appointed as Chief Executive Officer of Clinsys last November. Mr. Williams continues, “We have expanded and grown beyond the company we were even a year ago and continue building a unique client-focused organization with an enhanced service offering and a therapeutically focused direction. Our company branding must evolve to clearly communicate these changes along with our commitment to our sponsors’ success. Today, we are changing our name to Clinsys Clinical Research, reflecting our heritage and our new capabilities.”
“Our name now reflects the synergistic role of our global business groups in providing the right solutions for our sponsors in all phases of the drug development process. The name change brings clarity to our mission of providing the highest level of service and quality expected from the entire pharmaceutical industry,” said Mr. Williams.
Mr. Williams outlined his areas of primary focus. He said, “We continue to pursue our strategy to extend our global reach and to expand in our key therapeutic areas of oncology, cardiovascular, central nervous system, dermatology, respiratory and allergy/immunology.”
“Our full service subsidiary Clinsys India, Ltd., located in Noida, India, under the direction of Surinder Kher, MD, has grown to over 100 highly qualified, clinical research professionals, and continues to be of significant importance to our overall strategy as we provide our sponsors with the low cost, high quality solution for their Phase I-III clinical trials conducted in India. Also located in Noida, India, is our premier 52 bed Clinical Pharmacology Unit, under the direction of Karen Raudibaugh, providing our sponsors with a full range of Clinical Pharmacology services in support of bioavailability and bioequivalence studies, as well as bioanalytical sample analysis and pharmacokinetic and statistical support,” said Mr. Williams.
“To support our evolving global strategy and growth, key management assignments will evolve over the coming months. I’m pleased to announce the appointment of Ferrell Drewry as Chief Information Officer (CIO) and Vice President, Biometrics. In this new and expanded role for Clinsys, Ferrell is responsible for developing and implementing our enhanced IT infrastructure in support of our widening global strategy and will provide senior management to our Biometrics group. Ferrell previously held the position of CIO at INC Research, Inc.; Director of IT at PharmaResearch Corporation and held numerous management positions while with SAS Institute. Greg Dodds is appointed Senior Director, Business Development to lead our Global Business Development team. To support our global Clinical Pharmacology business, Karen Raudibaugh is promoted to Senior Director, Phase I and Early Clinical Development and is responsible for developing and executing a world class clinical pharmacology service,” said Mr. Williams.
“2007 will be an exciting and rewarding time for Clinsys Clinical Research, our sponsors and our staff. The ability to organize a global, highly skilled and professional team under a clear and defined mission of effective and efficient support of our sponsors is extremely rewarding,” said Mr. Williams.
About Clinsys Clinical Research, Inc.
Clinsys Clinical Research, Inc., a therapeutically focused clinical research organization is a Jubilant Organosys group company, headquartered in Berkeley Heights, New Jersey. Clinsys has multiple offices in the United States and India, offering pharmaceutical and biotechnology companies a broad range of clinical research services in support of Phase I-IV drug development: project management, medical and clinical monitoring, patient recruitment, site management, biostatistics, data management, drug safety, quality assurance, regulatory affairs and medical writing services. Clinsys has expertise in a wide range of highly specialized therapeutic areas including oncology, cardiovascular, respiratory, dermatology, respiratory and allergy/immunology. Clinsys India, Ltd., a subsidiary of Clinsys Clinical Research, Inc., provides extensive clinical research services for Phase I-III drug development, and operates a 52 bed clinical pharmacology unit which performs bioavailability and bioequivalence studies as well as bioanalytical sample analysis, clinical laboratory and pathology services. Targeted Clinical Staffing Solutions (TCSS - http://www.gotcss.com), a division of Clinsys Clinical Research, Inc., is a provider of professional staffing solutions and innovative partnering programs for the life sciences industry. For more information visit http://www.clinsyscro.com.
About Jubilant Organosys, Ltd.
Jubilant Organosys Ltd., is an integrated pharmaceutical services provider, one of the largest custom research and manufacturing services (CRAMS) and drug discovery and development services companies headquartered in India. The company has presence across the pharmaceuticals value chain right from drug discovery, functional chemistry, clinical research services to custom research and manufacturing services for advance intermediates and fine chemicals, Active Pharmaceutical Ingredients and Dosage Forms. Jubilant Organosys has more than 3,500 employees across organizations in India, the United States, Europe and China. It has four manufacturing locations in India and one in the United States. The company also has subsidiaries in the United States, China and Belgium. For more information visit http://www.jubl.com.
Contact: Donna Berk
(908) 464-7500
Clinsys, Inc.
CONTACT: Donna Berk, +1-908-464-7500, for Clinsys Clinical Research, Inc.
